Senator Mensch Provides Testimony in House on his Performance Based Budget Bill and in Senate on his Specialty Tier Prescription Drug Bill

Harrisburg –  Senator Bob Mensch (R-24) appeared before the House Appropriations Committee to offer testimony on his Performance Based Budget bill (SB 1341).

SB 1341 seeks to streamline and justify discretionary and state government spending by requiring departments and agencies to justify their budget requests for all existing, as well as proposed programs. This would allow the legislature and the Governor to properly budget for Pennsylvania state agencies and departments.

Specifically, the bill would require the Independent Fiscal Office (IFO) and the Budget Secretary to create a performance based budget plan each year that would designate certain departments and agencies to submit a list of data for the IFO to review. This information would then be presented to the Performance Based Budget (PBB) Board, who would review the recommendations from the report.

Following the report review, a series of hearings would be held on the IFO recommendations which would then be voted on by the PBB Board.

The agencies and departments will have the opportunity to comment and answer questions during the hearing process. This information will be used to show how each agency’s programs can be streamlined and made more efficient.

“Performance Based Budgeting will give us an objective, transparent, and effective approach to Pennsylvania’s budgetary needs,” said Mensch.  “I look forward to continuing the conversation on how to streamline our spending.”

SB 1341 was approved by the Senate on September 28, 2016.  It was then referred to the House Appropriations Committee.

Following the House Appropriations Hearing, Senator Mensch offered testimony on his Specialty Tier Prescription Drug legislation (SB 841) before the Senate Banking and Insurance Committee.  SB 841 seeks to cap co-payments for the out of pocket cost of specialty tier drugs.

“Many surrounding states have already taken steps to protect those that suffer from rare conditions such as hemophilia, hepatitis, multiple sclerosis, lupus, some cancers, rheumatoid arthritis and other serious chronic health issues from the high out of pocket costs,” said Mensch. “We need to limit these costs.  We’ve had the Legislative, Budget and Finance Committee conduct a study on specialty tier drug pricing and it is imperative that we implement their recommendations for the sake of Pennsylvanians.”
Constituents can access the Legislative, Budget and Finance Committee’s report on specialty tier prescription drugs here.
Additional information on SB 1341, SB 841, and additional bills sponsored by Senator Mensch can be found at

For more information on Senator Mensch’s legislation, visit  State updates can also be found on Senator Mensch’s Facebook at, or Twitter @SenatorMensch

CONTACT: Sarah Rasmussen  (215) 541-2388